C. Porta and C. Szczylik, “Tolerability of First-Line Therapy for Metastatic Renal Cell Carcinoma,” Cancer Treat Reviews, Vol. 35, No. 3, 2009, pp. 297-307.
doi:10.1016/j.ctrv.2008.12.003
-
TITLE:
Tumor Resistance to Molecularly Targeted Agents
AUTHORS:
James Chen, Peter S. Edelstein, Philip J. Johnson, Robert Lustig, Lucien Ooi
KEYWORDS:
Tumor Resistance, Signaling Pathway, Gene Pathway, Oncogene, Renal Cell Carcinoma
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.2 No.2,
July
8,
2011
ABSTRACT: Despite the development of new targeted cancer therapies, primary and secondary tumors continue to be a leading cause of suffering and mortality worldwide. The complexity and heterogeneity of malignancies ultimately result in tumor resistance to therapies, such as EGFR inhibitiors, anti-angiogenesis agents, and tyrosine kinase inhibitors. An example of targeted therapies for renal cell carcinoma is presented, including the SAE profile and efficacy of 6 targeted agents. Although survival is improved, resistance and an increased side effect profile diminish the benefits of these agents. New agents are needed which are pathway independent and which can overcome tumor resistance without adding to the side effect profile of current therapies.
Related Articles:
Evaluation of Targeted Therapy for Locally Advanced or Metastatic Renal Cell Carcinoma in Tunisia
Khaled Ben Ahmed, Amira Daldoul, Ghassen Tlili, Laila Ben Fatma, Olfa Gharbi, Mahdi Afrit, Jihene Fkih, Hammouda Boussen, Mounir Frikha, Faouzi Mosbah, Slim Ben Ahmed
DOI:
10.4236/ojgas.2016.67025
1,424 Downloads 2,273 Views Citations
Pub. Date:
July
27,
2016
Clinical Predictors of Cetuximab for First-Line Therapy of Metastatic Colorectal Cancer: A Single Institutional Retrospective Study
Yuki Morishita, Hiroaki Tanioka, Motoi Asano, Kotomi Tokuyama, Hiroko Okamoto, Tomohisa Okamoto, Takako Oda, Masatoshi Ohta, Masayuki Fukuzawa
DOI:
10.4236/jct.2017.89072
640 Downloads 1,192 Views Citations
Pub. Date:
September
12,
2017
Final Results of a Phase II Study of Bevacizumab, Cisplatin and Pemetrexed as First-Line Therapy for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer
Guillermo López Vivanco, Eider Azkona, Sergio Carrera, Aintzane Sancho, Itziar Rubio, Juan Manuel Mañé, Begoña Calvo, Unai Aresti, Aitziber Buque, Inés Marrodán, Alberto Muñoz
DOI:
10.4236/jct.2016.77047
1,891 Downloads 3,123 Views Citations
Pub. Date:
June
27,
2016
Efficacy and Safety of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma
Takahito Suyama, Takeshi Ueda, Satoshi Fukasawa, Atsushi Komaru, Masayuki Kobayashi, Yukio Naya, Naoki Nihei, Tomohiko Ichikawa
DOI:
10.4236/jct.2011.23046
4,594 Downloads 8,393 Views Citations
Pub. Date:
August
24,
2011
The role of diabetes mellitus in localized and metastatic renal cell carcinoma
Sandra Steffens, Christoph von Klot, Hendrik Egggers, Christoph Seidel, Gerd Wegener, Mark Schrader, Markus A. Kuczyk, Andres J. Schrader
DOI:
10.4236/jdm.2011.14014
3,979 Downloads 6,870 Views Citations
Pub. Date:
November
8,
2011
